Loading...
 
 26510 99294
 Λεωφόρος Σταύρου Νιάρχου, 455 00 Ιωάννινα

Latest posts from
What is New in Respiratory Medicine
Facebook Group

  • Saturday 05 Sep 2020

    Epithelial Resurfacing: The Bronchial Skin Peel

    Chronic bronchitis (defined as a chronic cough and sputum production on most days for 3 mo/yr for 2 consecutive years), or chronic mucus hypersecretion, has for decades been a neglected area for therapeutic intervention, with limited drug therapies available aside from antibiotics for infective exac...

     
  • Friday 04 Sep 2020

    The novel human coronavirus that is now named severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of coronavirus disease 2019 (COVID-19). The disease is mild in most people (∼80%). During the COVID-19 pandemic, in many countries the crisis has quickly overwhelmed the capaciti...

     
  • Saturday 05 Sep 2020

    Effects of a major deletion in the SARS-CoV-2 genome on the severity of infection and the inflammatory response: an observational cohort study

    A SARS-CoV-2 variant associated with milder infection?

    Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants with a 382-nucleotide deletion (∆382) in the open reading frame 8 (ORF8) region of the genome have been detected in Singapore and other countries. This study investigated the effect of this deletion on the clinical features of infection.

    The ∆382 variant of SARS-CoV-2 seems to be associated with a milder infection. The observed clinical effects of deletions in ORF8 could have implications for the development of treatments and vaccines.

    The ∆382 variant of SARS-CoV-2 seems to be associated with a milder infection. The observed clinical effects of deletions in ORF8 could have implications for the development of treatments and vaccines.

     
  • Saturday 05 Sep 2020

    Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

    Australia in the COVID-19 vaccine game?

    At 35 days, NVX-CoV2373 appeared to be safe, and it elicited immune responses that exceeded levels in Covid-19 convalescent serum. The Matrix-M1 adjuvant induced CD4+ T-cell responses that were biased toward a Th1 phenotype.

    Original Article from The New England Journal of Medicine — Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

     
  • Saturday 05 Sep 2020

    Early Clinically Important Improvement (ECII) and Exacerbation Outcomes in COPD Patients

    Our latest paper - from the aftermath of the FLAME trial

    ECII is a novel composite endpoint, based on clinically relevant improvement in lung function and PROs in the early phase of treatment intervention that may predict subsequent exacerbation risk and may be used in clinical trials.

    Approximately 18-20% of patients achieved ECII at Week 4 or 12 post-randomization according to any of the two definitions. The rate of subsequent exacerbations was lower in patients who achieved ECII at Week 4 (D1: ratio of rates [95% CI], 0.85 [0.74 to 0.98]; D2, 0.88 [0.77 to 1.00]) or at Week 12 (D1, 0.85 [0.74 to 0.98]; D2, 0.86 [0.75 to 1.00]) versus patients not achieving ECII. Patients who achieved ECII experienced longer time-to-first exacerbation between Week 4 or 12 to end of study. More patients achieved ECII with indacaterol/glycopyrronium versus salmeterol/fluticasone according to both definitions at Week 4 (D1, odds ratio [95% CI], 1.69 [1.40 to 2.04]; D2, 1.61 [1.34 to 1.93]), and 12 (D1, 2.01 [1.66 to 2.44]; D2, 1.80 [1.48 to 2.18]).

    ECII is a novel composite endpoint, based on clinically relevant improvement in lung function and PROs in the early phase of treatment intervention that may predict subsequent exacerbation risk and may be used in clinical trials.

     
  • Saturday 05 Sep 2020

    THE NATURE scientific magazine , fifteen days ago, expressed strong skepticism about the lack of documented and published data on the russian vaccine. Now we have some evidence. The Russian institute announced that 1billion vaccines have been ordered. We are waiting to see what happens next.

    The heterologous rAd26 and rAd5 vector-based COVID-19 vaccine has a good safety profile and induced strong humoral and cellular immune responses in participants. Further investigation is needed of the effectiveness of this vaccine for prevention of COVID-19.

     
  • Friday 04 Sep 2020

    An interesting case of respiratory failure secondary to occupational exposure in a 28-year-old male https://buff.ly/2Z8xRfs

    A 28-year-old male was admitted to the intensive care unit (ICU) for hypoxic respiratory failure requiring intubation and ventilation. He had been dyspnoeic for months leading up to admission with acute worsening 2 weeks prior and reported a 6-kg weight loss over the same time. Occasional dark spu...

     
  • Friday 04 Sep 2020

    Do Plasticizers within the Indoor Environment Increase Airway Allergen Responsiveness?

    There is an increasing appreciation that a wholistic consideration of the impact of air pollutants on health requires us to understand the continuum of exposures an individual may experience across the indoor and outdoor environment. This extends beyond the infiltration of ambient pollution into the...

     
  • Friday 04 Sep 2020

    Blue Briefing: Pulmonary Angiopathy in COVID-19 - Physiologic, Imaging and Hematologic Observations - YouTube

    In a new paper published in The American Journal of Respiratory and Critical Care Medicine, pulmonary and critical care experts report that the enlargement o...

     
  • Thursday 03 Sep 2020

    Lymphangioleiomyomatosis (LAM) is a rare diffuse cystic lung disease with robust diagnostic biomarkers and effective therapy

    Lymphangioleiomyomatosis (LAM) is a diffuse cystic lung disease. There are two main types of LAM: sporadic, and LAM associated with the tuberous sclerosis complex (TSC), which is caused by mutations in the TSC1 and TSC2 genes. LAM is characterised by cystic lung disease resulting in progressive dysp...

     
  • Thursday 03 Sep 2020

    Hasta ahora, las señales del SARS-CoV-2 son alentadoras. Varios equipos de investigadores se apresuraron a aislar anticuerpos neutralizantes de personas infectadas con el virus 3 ; la mayoría podría montar tal respuesta de anticuerpos a los pocos días de dar positivo. Y varias vacunas candidatas contra el SARS-CoV-2 provocan una fuerte respuesta de anticuerpos, una señal positiva de que las vacunas podrían generar inmunidad.

    Pero algunos científicos tienen salvedades sobre los datos preliminares. Las respuestas de los anticuerpos tendían a ser más altas en las personas con la infección más grave. Aquellos con infecciones leves, es decir, la mayoría de las personas que han tenido COVID-19, a veces producen pequeñas cantidades de anticuerpos neutralizantes. Este patrón se observa a menudo con los virus: es más probable que las infecciones más prolongadas y graves produzcan respuestas fuertes y duraderas. Esta es una de las razones por las que los coronavirus del resfriado común a veces no producen una inmunidad duradera, dice Shane Crotty, virólogo del Instituto La Jolla de Inmunología en California.

    Un trabajador de la salud toma muestras de sangre de un paciente para una prueba de anticuerpos contra el coronavirus Los niveles de anticuerpos aumentan poco después de una infección por coronavirus, pero luego disminuyen. Puede que eso no sea algo malo. Crédito: Alessandro Grassani / NYT / Redux / eyevine

    Luego está la cuestión de cuánto duran los anticuerpos. Cuando los investigadores rastrearon a los pacientes con COVID-19 a lo largo del tiempo, encontraron que la cantidad de anticuerpos alcanzó su punto máximo en los días posteriores a la aparición de los síntomas y luego comenzó a disminuir. En algunos participantes del estudio, los anticuerpos eran prácticamente indetectables en unos tres meses 4 , 5 . Varios medios de comunicación importantes informaron esto como una pérdida de inmunidad, diciendo que complicaría los esfuerzos de vacunación.

    Sin embargo, muchos inmunólogos encontraron esa declaración un poco prematura. Los datos mostraron una respuesta perfectamente normal a una infección viral, dice Luis Barreiro de la Universidad de Chicago en Illinois, quien estudia la evolución de las respuestas inmunes a los patógenos. Cuando un virus ataca, estimula la proliferación de células B que producen anticuerpos capaces de reconocer partes del virus. Pero una vez que la infección desaparece, los niveles de anticuerpos suelen disminuir. “Existe mucho miedo”, dice Miles Carroll, especialista en enfermedades infecciosas de Public Health England en Porton Down, Reino Unido. "Pero creo que, en general, es una respuesta inmune bastante sólida".

    Las terapias con anticuerpos podrían ser un puente hacia una vacuna contra el coronavirus, pero ¿se beneficiará el mundo? Para determinar qué tan importante podría ser esa disminución, los investigadores aún necesitan saber cuántos anticuerpos se necesitan para defenderse con éxito del SARS-CoV-2. "Incluso pequeñas cantidades de anticuerpos pueden ser potencialmente protectores", dice Mala Maini, inmunóloga viral del University College London.

    Viral immunologists say that results so far have been predictable — here’s why that’s good news.

     
  • Thursday 03 Sep 2020

    Positive association of Angiotensin II Receptor Blockers, not Angiotensin-Converting Enzyme Inhibitors, with an increased vulnerability to SARS-CoV-2 infection in patients hospitalized for suspected COVID-19 pneumonia.

    Significant interaction between ARBs and ACEIs for the risk of COVID-19 was observed in patients aged>60, women, and hypertensive patients. ACEIs and ARBs are not similarly associated with the COVID-19. In this retrospective series, patients with COVID-19 pneumonia received more frequently a previous treatment with ARBs, than patients without COVID-19.

    Background. Angiotensin converting enzyme (ACE) type 2 is the receptor of SARSCoV-2 for entry into lungs cells. Because ACE-2 may be modulated by ACE inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs), there is concern that patients treated with ACEIs and ARBs are at higher risk for COVI...

     
  • Wednesday 02 Sep 2020

    Corticosteroids in critically ill COVID-19 patients A meta-analysis and 3 new RCTs published in JAMA today and an accompanying editorial

    https://jamanetwork.com/journals/jama/fullarticle/2770279

     
  • Wednesday 02 Sep 2020

    Six months into the outbreak, Nature looks at the pressing questions that researchers are tackling.

     
  • Wednesday 02 Sep 2020

    The coronavirus disease 2019 (COVID-19) pandemic has dramatically changed the lives of people around the globe since it appeared in Wuhan, China, at the beginning of December 2019. The burden of disease and its death toll have had an unprecedented impact on the healthcare, economic and financial sys...

     
  • Wednesday 02 Sep 2020

    Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a newly identified agent foisted upon humanity and responsible for the contagious affliction, coronavirus disease 2019 (COVID-19) [1] that has rapidly evolved into a pandemic testing to the limits, and sometimes beyond, the capacity to....

     
  • Wednesday 02 Sep 2020

    Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the agent responsible for the recent coronavirus disease 2019 (COVID-19) pandemic. The virus is predominantly spread through large droplets. The clinical features of COVID-19 are varied, ranging from asymptomatic to acute respiratory di...

     
  • Wednesday 02 Sep 2020

    Blood Eosinophil Counts in Clinical Trials for Chronic Obstructive Pulmonary Disease

    An excellent overview of the clinical trial data from the COPD Foundation Eosinophil Working Group

    OPEN ACCESS

    Chronic obstructive pulmonary disease (COPD) is a complex condition with pathophysiology and clinical characteristics that vary in presence and severity between patients (1). This variability contributes to the range of treatment responses observed for patients with COPD for both established and exp...

     
  • Wednesday 02 Sep 2020

    Bronchial Rheoplasty for Treatment of Chronic Bronchitis

    Twelve-Month Results from a Multicenter Clinical Trial

    This study provides proof of concept for the safety and technical feasibility of bronchial rheoplasty, an endoscopic technique using nonthermal pulsed electrical fields to ablate airway mucosa and reduce airway mucus production in the treatment of CB. Reductions in goblet cell hyperplasia and changes in patient-reported quality-of-life measures were observed after the procedure.

     
  • Wednesday 02 Sep 2020

    Hot off the press, the 2006 guideline update: global physiology and pathophysiology of cough.

    https://journal.chestnet.org/article/S0012-3692(20)34317-8/fulltext

    The purpose of this state-of-the-art review is to update the American College of Chest Physicians (CHEST) 2006 guideline on global physiology and pathophysiology of cough.

     
317 Αντικείμενα. Σελίδα 8/16
3 4 5 6 7 8 9 10 11 12
 
Developed by LogicOne